XTL BIOPHARMACEUTICALS LTD (XTLB)
Institutional ownership reported to the SEC as of Q2 2026, across 31 quarters.
Institutions report 7,566 shares against 946,243,356 outstanding. Shares only - option lines are excluded, which is why this can be compared with the company at all. The count comes from the cover page of the company's own most recent report, so it is dated when that was filed rather than at quarter end. Share count carried from an earlier filing (cy2025q4i).
Options share is the part of reported value carried in derivative lines rather than shares. A high figure means institutions are expressing a view on this security without owning much of it.
Holders
| Filer | Value | Shares | Their book | Held | Change |
|---|---|---|---|---|---|
| RHUMBLINE ADVISERS | $17.0K | 6,228 | 0.00% | 2q | +4.0% |
| GAMMA Investing LLC | $3.3K | 1,213 | 0.00% | 2q | -64.2%-$5.9K |
| UBS Group AG | $341 | 125 | 0.00% | new | NEW |
Quarter by quarter
Coverage begins with the quarter ending 2018-12-31. Earlier filings exist only as occasional late amendments, too sparse to describe a market, so they are not shown.
| Quarter | Holders | Value | Shares | New | Added | Trimmed | Options |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 3 | $20.7K | 7,566 | 1 | 1 | 1 | 0.0% |
| Q1 2026 | 5 | $55.4K | 22,980 | 5 | 0 | 0 | 0.0% |
| Q4 2025 | 5 | $75.9K | 130,839 | 3 | 1 | 1 | 0.0% |
| Q3 2025 | 4 | $33.0K | 226,923 | 0 | 0 | 2 | 0.0% |
| Q2 2025 | 4 | $34.3K | 228,496 | 1 | 1 | 1 | 0.0% |
| Q1 2025 | 4 | $60.9K | 248,304 | 1 | 0 | 1 | 0.0% |
| Q4 2024 | 3 | $60.1K | 228,193 | 0 | 1 | 1 | 0.0% |
| Q3 2024 | 3 | $79.9K | 231,858 | 0 | 1 | 1 | 0.0% |
| Q2 2024 | 4 | $130.9K | 253,058 | 1 | 1 | 1 | 0.0% |
| Q1 2024 | 4 | $388.9K | 138,398 | 1 | 2 | 0 | 0.0% |
| Q4 2023 | 4 | $80.9K | 80,096 | 1 | 1 | 1 | 0.0% |
| Q3 2023 | 4 | $37.0K | 239,879 | 1 | 1 | 1 | 0.0% |
| Q2 2023 | 3 | $41.6K | 240,259 | 1 | 0 | 1 | 0.0% |
| Q1 2023 | 2 | $55.0K | 240,659 | 0 | 0 | 1 | 0.0% |
| Q4 2022 | 3 | $52.6K | 242,159 | 1 | 0 | 1 | 0.0% |
| Q3 2022 | 3 | $492.0K | 443,047 | 0 | 0 | 1 | 0.0% |
| Q2 2022 | 3 | $678.0K | 446,547 | 0 | 0 | 1 | 0.0% |
| Q1 2022 | 4 | $1.0M | 447,859 | 1 | 0 | 1 | 0.0% |
| Q4 2021 | 4 | $1.3M | 472,127 | 0 | 1 | 1 | 0.0% |
| Q3 2021 | 6 | $2.1M | 487,426 | 2 | 0 | 2 | 0.0% |
| Q2 2021 | 5 | $2.0M | 500,698 | 0 | 0 | 2 | 0.0% |
| Q1 2021 | 6 | $1.7M | 508,501 | 2 | 1 | 1 | 0.0% |
| Q4 2020 | 4 | $1.4M | 474,130 | 1 | 1 | 0 | 0.0% |
| Q3 2020 | 4 | $848.0K | 446,243 | 1 | 1 | 0 | 0.0% |
| Q2 2020 | 3 | $699.0K | 439,607 | 0 | 1 | 0 | 0.0% |
| Q1 2020 | 3 | $515.0K | 437,707 | 0 | 1 | 0 | 0.0% |
| Q4 2019 | 4 | $596.0K | 435,831 | 0 | 1 | 1 | 0.0% |
| Q3 2019 | 6 | $687.0K | 481,451 | 1 | 0 | 1 | 0.0% |
| Q2 2019 | 5 | $927.0K | 463,299 | 0 | 1 | 1 | 0.0% |
| Q1 2019 | 5 | $1.1M | 464,799 | 0 | 1 | 1 | 0.0% |
| Q4 2018 | 6 | $804.0K | 464,842 | 1 | 1 | 0 | 0.0% |